Chemoprevention of bladder cancer

H. Barton Grossman, J. Stephen Jones, Michael L. Blute, Louis S. Liou, Mark S. Soloway, Victor E. Reuter

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Chemoprevention of cancer can be accomplished using primary, secondary, or tertiary strategies. Tertiary chemoprevention has been the predominant approach for bladder cancer and addresses the need for preventing the occurrence of second primary cancers in patients who have previously been treated for cancer. Because non-muscle-invasive bladder cancer is associated with a high risk of recurrence, tertiary chemoprevention has been studied in this population. Although considerable preclinical data has demonstrated the feasibility of this approach, application to the clinical setting has met with limited success. This review discusses chemoprevention of bladder cancer and focuses on the drugs used in chemoprevention investigations and clinical study design.

Original languageEnglish (US)
Pages (from-to)19-22
Number of pages4
JournalUrology
Volume67
Issue number3 SUPPL. 1
DOIs
StatePublished - Mar 2006

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Chemoprevention of bladder cancer'. Together they form a unique fingerprint.

  • Cite this

    Grossman, H. B., Jones, J. S., Blute, M. L., Liou, L. S., Soloway, M. S., & Reuter, V. E. (2006). Chemoprevention of bladder cancer. Urology, 67(3 SUPPL. 1), 19-22. https://doi.org/10.1016/j.urology.2006.01.015